Latest Conference Articles

In a four-year study of over 1,600 patients who had outpatient head CTs, head CT angiography and/or brain MRI to assess cognitive impairment, researchers found that Black patients were over 9 percent less likely than White patients and over 16 percent less likely than Hispanic patients to receive brain MRI.

Catch up on the top radiology content of the past week.

Artificial intelligence (AI) assessments of chest X-rays identified 28 percent of a 17,000 plus cohort of never-smokers as being at high-risk for lung cancer, according to research to be presented at the annual Radiological Society of North America (RSNA) conference next week.

Through assessment of diffusion tensor MRI of the brain, a new AI system reportedly offers a 97 percent sensitivity rate in diagnosing autism in children between two to four years of age, according to research to be presented at the annual Radiological Society of North America (RSNA) conference next week.

Utilizing computed tomography (CT) guidance, researchers have found that performing a minimally invasive anesthetic injection into the stellate ganglia may help address parosmia due to COVID-19, according to study results that will be presented at the annual Radiological Society of North America (RSNA) conference next week.

In a recent video interview, Ashesh Jani, M.D., discussed a subset analysis from the SPOTLIGHT trial that examined the utility of the PET PSMA agent flotufolastat F 18 (Posluma) for detecting prostate cancer recurrence in men with low PSA levels lower than 1 ng/mL.

In reportedly the first randomized study to compare hypofractionated radiation treatment versus conventional radiation treatment for women who had breast reconstruction procedures after mastectomy, researchers at the recent ASTRO conference noted similar rates of cancer recurrence, chest wall toxicity and patient well-being.

Researchers noted a 20.1 percent incidence of bone-only metastasis in a cohort of men with castration-resistant prostate cancer, according to findings from research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

The Pulmonary Embolism (PE) Triage and Notification (PETN) module with RapidAI’s RapidPE platform reportedly demonstrated over 90 percent sensitivity and specificity rates for detection of central PE on computed tomography (CT), according to multicenter study findings presented at the 9th Annual Pulmonary Embolism Symposium.

Twice-a-day consumption of reconstituted grape powder provides significant long-term benefit in preserving cerebral metabolism for people with mild cognitive decline, according to research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

The PSMA PET agent 64Cu SAR-bisPSMA detected a higher number of prostate cancer lesions and had a significantly higher SUVmax and SUVmean than 68Ga PSMA-11 PET/CT, according to initial data from a prospective multisite study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.

Featuring sector and linear arrays, the FDA-cleared Vscan Air SL ultrasound device reportedly enables cardiac and vascular assessments at the point of care.

In interviews at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers discussed the potential impact of ultra-high resolution brain positron emission tomography (PET) as well as emerging PET radiotracers for detecting coronary artery disease in obese patients and diagnosing clear cell renal cell carcinoma.

In an analysis of patients with intraprostatic/prostate bed findings of biochemical prostate cancer recurrence, the use of 18F-DCFPyL PET/CT led to an 82.3 percent cancer detection rate in comparison to 80 percent for multiparametric MRI, according to research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

In a video interview, Hong Song, M.D., Ph.D., discussed retrospective research, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, that evaluated the combination of artificial intelligence (AI)-based software and the PSMA agent piflufolastat F 18 to help quantify prostate cancer lesions and associations with biochemical progression-free survival.

The PET radiotracer 18F-PSMA-1007 facilitated detection of at least one suspicious lesion for metastasis in nearly half of a cohort of 160 patients with prostate cancer, according to research presented recently at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.

Catch up on the most viewed content at Diagnostic imaging in July 2023.

Catch up on emerging research findings presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2023 conference.

In a recent interview at the SNMMI conference, Roger Lecomte, Ph.D., and Vincent Doyon discussed the advent of ultra-high resolution (UHR) brain positron emission tomography (PET), which reportedly offers double the spatial resolution of conventional PET and may facilitate earlier detection of Alzheimer’s disease and other conditions.

Catch up on recent interviews with Jeremie Calais, M.D. MSc, Krishna Patel, M.D., Phillip Kuo, M.D. Ph.D, and more faculty from the Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2023 conference.

Catch up on the top radiology content of the past week.

In a recent interview at the SNMMI conference, Krishna Patel, M.D., discussed the benefits of the PET perfusion radiotracer agent 18F-flurpiridaz and new research findings showing the agent’s increased sensitivity and specificity in diagnosing coronary artery disease in obese patients.

The use of single-photon emission computed tomography (SPECT)/computed tomography (CT) to monitor the effectiveness of Lu-177-PSMA (Pluvicto) in treating prostate cancer led to a greater than 50 percent decrease in prostate-specific antigen (PSA) level for 60 percent of patients in a new study, noted Andrew Nguyen, MBBS, FRACP, AANMS, in a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.

Carch up on the top radiology content of the past week.

Employing a hybrid positron emission tomography (PET)/magnetic resonance imaging (MRI) model to assess predictive features of Alzheimer’s disease (AD), researchers noted a 100 percent sensitivity rate and a 93 percent sensitivity rate for distinguishing between AD and normal cognition, according to a study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.

In an interview at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Jeremie Calais, M.D., MSc discussed promising research findings for the use of the positron emission tomography (PET) imaging agent 89ZR-DFO-girentuximab for diagnosing clear cell renal cell carcinoma.

New research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference suggests that neuroreceptor differences in reactions to visual food cues between obese people and normal-weight individuals may improve the understanding of underlying mechanisms that contribute to obesity.

In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D., Ph.D, F.A.C.R., discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.